Maze Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Maze Therapeutics Inc Unternehmen

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Maze Therapeutics Inc Informationen



BörsenkürzelMAZE

Name des UnternehmensMaze Therapeutics Inc

IPO-datumJan 31, 2025

CEODr. Jason V. Coloma, Ph.D.

Anzahl der mitarbeiter125

WertpapierartOrdinary Share

GeschäftsjahresendeJan 31

Addresse171 Oyster Point Boulevard, Suite 300

StadtSOUTH SAN FRANCISCO

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl94080

Telefon16508505070

Websitehttps://www.mazetx.com/

BörsenkürzelMAZE

IPO-datumJan 31, 2025

CEODr. Jason V. Coloma, Ph.D.

Führungskräfte von Maze Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jonathan E. Lim, M.D.

Independent Director

328.70K

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

103.72K

--

Mr. Atul Dandekar

Chief Strategy and Business Officer

8.94K

--

Mr. Neil Exter

Independent Director Nominee

--

Dr. Charles Homcy, M.D.

Co-Founder, Director

--

Dr. Jason V. Coloma, Ph.D.

Chief Executive Officer, Director

--

Mr. Alan B. Colowick, M.D.

Independent Director

--

Dr. Richard H. Scheller, Ph.D.

Independent Director

--

-100.00%

Ms. Jillian Connell

Investor Relations

--

Dr. Jamie Brush, M.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Jonathan E. Lim, M.D.

Independent Director

328.70K

--

Dr. Sekar (Sek) Kathiresan, M.D.

Independent Director

103.72K

--

Mr. Atul Dandekar

Chief Strategy and Business Officer

8.94K

--

Mr. Neil Exter

Independent Director Nominee

--

Dr. Charles Homcy, M.D.

Co-Founder, Director

--

Dr. Jason V. Coloma, Ph.D.

Chief Executive Officer, Director

--

Umsatzaufteilung

FY2025Q2

FY2024

Keine Daten

Nach RegionUSD

Name

Umsatz

Anteil

United States

0.00

0.00%

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Mon, Nov 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Third Rock Ventures, LLC

11.27%

Frazier Life Sciences Management, L.P.

9.49%

ARCH Venture Partners

8.56%

Deep Track Capital LP

8.21%

Matrix Capital Management Company, LP

5.17%

Andere

57.30%

Aktionäre

Anteil

Third Rock Ventures, LLC

11.27%

Frazier Life Sciences Management, L.P.

9.49%

ARCH Venture Partners

8.56%

Deep Track Capital LP

8.21%

Matrix Capital Management Company, LP

5.17%

Andere

57.30%

Aktionärstypen

Aktionäre

Anteil

Venture Capital

31.81%

Private Equity

14.60%

Hedge Fund

13.75%

Investment Advisor/Hedge Fund

10.99%

Investment Advisor

6.38%

Individual Investor

1.88%

Endowment Fund

1.32%

Family Office

1.00%

Pension Fund

0.05%

Andere

18.21%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

111

39.53M

83.57%

-194.63K

2025Q2

100

42.58M

97.22%

+13.88M

2025Q1

93

44.69M

102.04%

+15.27M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Third Rock Ventures, LLC

7.02M

16.02%

--

Jun 30, 2025

Frazier Life Sciences Management, L.P.

4.57M

10.42%

+115.94K

+2.60%

Jun 30, 2025

ARCH Venture Partners

4.12M

9.4%

--

Jun 30, 2025

Deep Track Capital LP

3.95M

9.01%

+679.78K

+20.79%

Jun 30, 2025

Matrix Capital Management Company, LP

2.49M

5.67%

--

Jun 30, 2025

Foresite Capital Management, LLC

2.46M

5.6%

--

Jun 30, 2025

Alphabet, Inc.

2.41M

5.5%

--

Jun 30, 2025

Andreessen Horowitz

1.70M

3.88%

--

Jun 30, 2025

Janus Henderson Investors

1.40M

3.2%

+154.89K

+12.43%

Jun 30, 2025

The Vanguard Group, Inc.

419.61K

0.96%

-246.94K

-37.05%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Virtus LifeSci Biotech Clinical Trials ETF

1.38%

ALPS Medical Breakthroughs ETF

0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

0.42%

iShares Micro-Cap ETF

0.1%

iShares Russell 2000 Value ETF

0.03%

Proshares Ultra Russell 2000

0.02%

ProShares UltraPro Russell2000

0.02%

ProShares Hedge Replication ETF

0.02%

Global X Russell 2000 ETF

0.02%

iShares Russell 2000 ETF

0.01%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil1.38%

ALPS Medical Breakthroughs ETF

Anteil0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

Anteil0.42%

iShares Micro-Cap ETF

Anteil0.1%

iShares Russell 2000 Value ETF

Anteil0.03%

Proshares Ultra Russell 2000

Anteil0.02%

ProShares UltraPro Russell2000

Anteil0.02%

ProShares Hedge Replication ETF

Anteil0.02%

Global X Russell 2000 ETF

Anteil0.02%

iShares Russell 2000 ETF

Anteil0.01%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten